Arrhythmias, notably atrial and ventricular fibrillation, represent major public health burdens for which available therapies are incompletely effective. Remarkable progress has been made in identifying disease genes in rare monogenic arrhythmia syndromes and in identifying clinical markers of arrhythmia risk (including family history) in large populations.

The goal of studies in the Pharmacology of Antiarrhythmic Therapy Center is to exploit these advances to further our understanding of genetic predictors of variability in arrhythmia phenotypes, and their variable responses to drug therapy. In this center, we have adopted an association study paradigm, shown below. Thus, the major goals are (1) polymorphism discovery and characterization; (2) patient accrual; and (3) analysis using genetic epidemiology.

Click on image to view antiarrhythmic drug pathways

Overview News People Projects Data Tools Publications Events Links Contact

Home